Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026
Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Fineline Cube Aug 17, 2026
Company Medical Device

Johnson & Johnson MedTech’s QDOT Catheter Approved in China for Atrial Fibrillation

Fineline Cube Feb 24, 2023

Johnson & Johnson MedTech’s next-generation QDOT micro diagnostic/ablation deflectable tip catheter, a disposable pressure monitoring...

Company Deals

Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto

Fineline Cube Feb 24, 2023

US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...

Company Deals

ConjuStar Peptide-Drug Conjugate Angel Financing

Fineline Cube Feb 24, 2023

Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...

Policy / Regulatory

Guangdong Adds Hospitals to GBA Drug and Device Green Channel

Fineline Cube Feb 23, 2023

The Health Commission of Guangdong Province (GDHC) has released a second list of designated medical...

Company Drug

Zai Lab to Present Zejula OS Study Results at ESMO Congress

Fineline Cube Feb 23, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...

Company Deals

Huadong Medicine Expands Global Partnership with Scohia Pharma for SCO-094

Fineline Cube Feb 23, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) and Japanese firm Scohia Pharma Inc. have announced...

Company Drug

Zai Lab’s SUL-DUR NDA Accepted for Review by NMPA

Fineline Cube Feb 23, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has revealed that a New Drug Application...

Company Deals R&D

Changchun BCHT Biotechnology and IMB CAMS Enter Five-Year Research Pact

Fineline Cube Feb 23, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a five-year scientific research cooperation...

Company Deals

Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca

Fineline Cube Feb 23, 2023

China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...

Company

Legend Biotech No Longer Faces Delisting from Nasdaq

Fineline Cube Feb 22, 2023

China-based Legend Biotech Corporation (NASDAQ: LEGN) has released a notice stating that it is no...

Company Drug

Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA

Fineline Cube Feb 22, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...

Company Medical Device

MicroPort CardioFlow’s TAVI Product Approved in Thailand

Fineline Cube Feb 22, 2023

China-based MicroPort Scientific Corp’s (HKG: 0853) spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has...

Company Deals

TransThera Biosciences Completes Series D+ Financing Round

Fineline Cube Feb 22, 2023

China’s Nanjing TransThera Sciences (Nanjing), Inc. has announced the completion of a Series D+ financing...

Company Drug

Shanghai Pharmaceuticals’ WST01 Receives FDA Clinical Clearance

Fineline Cube Feb 22, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced receiving clinical clearance from the...

Company Deals

Huahai Pharma Raises Funds for Digital Manufacturing and API Platform

Fineline Cube Feb 22, 2023

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) plans to raise RMB 1.56 billion (USD...

Company Deals R&D

Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center

Fineline Cube Feb 22, 2023

Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...

Company Drug

Huadong Medicine’s Patent Challenge Against Novo Nordisk’s Ozempic Heads to Hearing

Fineline Cube Feb 22, 2023

February 23 will mark the oral hearing phase for the patent challenge case brought by...

Company Drug

Neurophth’s NR082 Gene Therapy Completes Phase III Enrollment

Fineline Cube Feb 22, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced the completion of all-patient enrollment and...

Company Drug

Sinovac’s Hepatitis A Vaccine Healive Approved in Egypt

Fineline Cube Feb 22, 2023

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced obtaining market approval from the Egyptian Drug...

Company Medical Device

Asieris’ Uro-G Bladder Endoscope Catheter Awaits NMPA Approval

Fineline Cube Feb 22, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...

Posts pagination

1 … 602 603 604 … 709

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
  • CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
  • Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
  • Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.